1. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
- Author
-
Beatriz Tormo, Natalia Fernández Puga, Marta Hernández-Conde, Christie Perelló, María Trapero-Marugán, Carlos Fernández Carrillo, Luis M. Rodríguez, Carlos Ferre Aracil, Elba Llop, Javier Abad, Enrique Fraga, Marta López Gomez, José Luis Martínez-Porras, and José Luis Calleja Panero
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Biopsy ,Liver fibrosis ,Observational Study ,Disease ,Intra-Abdominal Fat ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,medicine ,Humans ,In patient ,Visceral fat ,Obesity ,business.industry ,Fatty liver ,Non alcoholic ,General Medicine ,Middle Aged ,medicine.disease ,Fibrosis ,Metabolic syndrome ,Cross-Sectional Studies ,030220 oncology & carcinogenesis ,Bioimpedanciometry ,Elasticity Imaging Techniques ,030211 gastroenterology & hepatology ,Female ,business ,Significant fibrosis - Abstract
BACKGROUND Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression. AIM To investigate the role of bioelectrical impedance-estimated visceral fat (VF) in assessing NAFLD severity. METHODS In this cross-sectional study, patients with biopsy-proven NAFLD were prospectively included. All patients underwent anthropometric evaluation, blood tests and bioelectrical impedance analysis. RESULTS Between 2017 and 2020, 119 patients were included [66.4% male, 56 years (SD 10.7), 62.2% obese, 61.3% with metabolic syndrome]. Sixty of them (50.4%) showed significant fibrosis (≥ F2) in liver biopsy. Age, VF and metabolic syndrome were associated with significant fibrosis (61 years vs 52 years, 16.4 vs 13.1, 73.3% vs 49.2%, respectively; P < 0.001 for all). In the multivariate analysis, VF and age were independently associated with significant fibrosis (VF, OR: 1.11, 95%CI: 1.02-1.22, P = 0.02; age, OR: 1.08, 95%CI: 1.03-1.12, P < 0.01). A model including these variables showed and area under the receiver operating characteristic curve (AUROC) of 0.75, which was not inferior to transient elastography or NAFLD fibrosis score AUROCs. We developed a nomogram including age and VF for assessing significant fibrosis in routine practice. CONCLUSION VF is a surrogate marker of liver fibrosis in patients with NAFLD. Bioelectrical impedance analysis is an inexpensive and simple method that can be combined with age to guide patient referral when other resources may be unavailable.
- Published
- 2020